Immix Biopharma (IMMX) EBITDA (2021 - 2026)
Immix Biopharma (IMMX) posted EBITDA of -$10.8 million for Q1 2026, up 0.82% sequentially from -$10.9 million in Q4 2025, and down 130.71% YoY from $35.2 million in Q1 2025.
Immix Biopharma (IMMX) EBITDA (2021 - 2026) Analysis & Trends
Immix Biopharma has reported EBITDA for 6 years, with the latest figure at -$10.8 million in Q1 2026.
- Quarterly EBITDA fell 130.71% year-over-year to -$10.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$36.1 million (down 65.74% YoY) and the FY2025 annual result came in at -$30.0 million, down 32.11% from the prior year.
- EBITDA rose to -$10.8 million in Q1 2026 per IMMX's latest filing, from -$10.9 million in the prior quarter.
- Over five years, EBITDA peaked at -$1.3 million in Q1 2022 and troughed at -$10.9 million in Q4 2025.
- A 5-year average of -$5.2 million and a median of -$4.7 million in 2024 frame the typical range for EBITDA.
- The sharpest annual moves came in 2022 and 2025: EBITDA tumbled 718.38% in 2022, then gained 16.23% in 2025.
- Over 5 years, EBITDA stood at -$3.8 million in 2022, then sank by 41.67% to -$5.4 million in 2023, then increased by 7.23% to -$5.0 million in 2024, then tumbled by 118.43% to -$10.9 million in 2025, then increased by 0.82% to -$10.8 million in 2026.
- According to Business Quant data, EBITDA over the past three periods registered -$10.8 million, -$10.9 million, and -$7.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Immix Biopharma | 784.75 Mn | 784.75 Mn | - | -12.46 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -12.46 Mn |
| Mar 31, 2026 | -10.80 Mn |
| Dec 31, 2025 | -10.89 Mn |
| Sep 30, 2025 | -7.66 Mn |
| Jun 30, 2025 | -6.72 Mn |
| Mar 31, 2025 | -4.68 Mn |
| Dec 31, 2024 | -4.99 Mn |
| Sep 30, 2024 | -7.39 Mn |
| Jun 30, 2024 | -4.70 Mn |
| Mar 31, 2024 | -5.59 Mn |
| Dec 31, 2023 | -5.38 Mn |
| Sep 30, 2023 | -4.52 Mn |
| Jun 30, 2023 | -3.72 Mn |
| Mar 31, 2023 | -2.52 Mn |
| Dec 31, 2022 | -3.79 Mn |
| Sep 30, 2022 | -1.53 Mn |
| Jun 30, 2022 | -1.56 Mn |
| Mar 31, 2022 | -1.33 Mn |
| Dec 31, 2021 | -598,338.00 |
| Sep 30, 2021 | -347,991.00 |